A key finding of this study is the increased incidence of diarrhea with long-acting and ultra-long-acting GLP-1RAs, particularly semaglutide which a recent meta-analysis similarly found to have a higher diarrhea risk compared to lixisenatide, liraglutide, and exenatide, though lower than tirzepatide (risk ratios 1.661.80 vs
MrchLSSkovlundCWHannafordPCIversenLFieldingSLidegaard
Theres no listed drug interaction, and the Wegovy prescribing information notes no clinically relevant effect on gastric emptying at the 2.4 mg dose
And, even if I knew how to help people attain peak performance in their fitness, their careers, or their sex lives, Im not sure thats my job
The research is clear, and the answer matters whether you're considering pausing treatment, planning a transition, or just weighing your long-term options